
Attorney General Ken Paxton has been making moves on the chessboard of justice, securing a bankruptcy reorganization plan for Purdue Pharma that's set to flip the script on how the opioid crisis heavyweight is held accountable. According to a release from the Attorney General Paxton, the plan will give birth to Knoa Pharma, a new entity poised to keep manufacturing OxyContin, but with reins pulled tight to keep misuse in check.
The framework is also designed to transfer insurance and third-party claims to a Master Creditor Trust, a move that's supposed to bulk up oversight and keep future legal challenges on the straight and narrow. Attorney General Paxton's take on the deal is pretty clear, saying, "This plan reflects years of working to secure justice for the families and communities devastated by the opioid crisis," he pointedly explained in his news release, emphasizing the significance of the newfound legal stranglehold on Purdue and the Sackler family.
With Texas set to bag about $294 million over 15 years from the deal, the Lone Star State's war chest against the opioid epidemic is looking a lot healthier. These funds are earmarked to bolster efforts in opioid abatement, treatment, and prevention—a much-needed infusion of support for communities shredding under the weight of addiction and loss. The news comes on the heels of a $7.4 billion global settlement arranged by Paxton, a sum that puts other Big Pharma skirmishes in the shade, as reported by the Attorney General Paxton.
The deal is gripping particularly because of its timing—set to come into effect in spring 2026—which gives those impacted by the opioid crisis a tangible timeline to clutch onto. Paxton summed up the intentions behind this historical maneuver, "The framework helps ensure that Purdue and the Sackler family will face consequences for the damage they caused, secures critical resources to help Texans recover, and also supports our state’s efforts to combat this deadly epidemic," as per the Attorney General Paxton.









